Ovid Therapeutics Inc. (OVID)

Market Cap	97.42M
Revenue (ttm)	6.65M
Net Income (ttm)	-37.52M
Shares Out	71.11M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,189,495
Open	1.430
Previous Close	1.450
Day's Range	1.360 - 1.470
52-Week Range	0.243 - 2.010
Beta	0.36
Analysts	Strong Buy
Price Target	3.13 (+128.47%)
Earnings Date	Nov 13, 2025

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2017
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: OVID
• Website: https://www.ovidrx.com

Financial Performance

In 2024, Ovid Therapeutics's revenue was $566,000, an increase of 44.39% compared to the previous year's $392,000. Losses were -$25.98 million, -49.49% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $3.13, which is an increase of 128.47% from the latest price.

Price Target

$3.13

(128.47% upside)

Analyst Consensus: Strong Buy